What is the deadline for investors to join the class, and what steps must they take? | TEM (Aug 11, 2025) | Candlesense
TEM

What is the deadline for investors to join the class, and what steps must they take?

Class‑action deadline:

Investors who bought Tempus AI (NASDAQ TEM) common shares between 6 Aug 2024 and 27 May 2025 must file a claim by Tuesday, 12 August 2025 to be included in the lead‑class‑action lawsuit.

How to join the class

  1. Contact the lead counsel – Reach out to Robbins Geller Rudman & Dowd LLP (the firm handling the case).
  2. Submit a claim form – Complete the online/‑paper “Notice of Claim” that the firm provides, attaching proof of purchase (trade‑confirmation statements, brokerage statements, or trade‑ticket receipts) showing a purchase date within the class period.
  3. Retain documentation – Keep copies of the filed claim and any correspondence, as the firm may request additional evidence later.

Trading implications

The announcement that a sizable group of shareholders can now act as lead plaintiffs often triggers a short‑term price bounce for the target stock, as the market prices in the potential for a larger settlement fund and the associated upside for claim‑holders. Tempus AI has been trading in a relatively tight range (≈ $12‑$15) on relatively light volume, with the 20‑day SMA still hovering near $13.5 and the RSI at the 45‑mark—signalling no immediate oversold/overbought pressure. If the class‑action proceeds and a settlement materialises, the stock could see a mid‑single‑digit rally on the news, especially if the settlement amount is sizable relative to the company’s market cap.

From a technical standpoint, a break above the $14 resistance on strong volume would confirm bullish momentum, while a failure to hold that level could indicate the market is discounting the legal development. Until the claim‑filing deadline passes, the risk‑reward balance for short‑term traders leans toward a modest long position (or a “buy‑the‑dip” if the price retreats below $13 on the deadline), while longer‑term investors should monitor the settlement progress and any subsequent SEC filings for a clearer view of the fundamental impact on Tempus AI’s valuation.

Other Questions About This News

What is the potential financial impact of the lawsuit on Tempus AI's balance sheet and cash flow? How likely is it that the class action will result in a settlement versus a trial, and what timeframe could that entail? What is the estimated size of the potential settlement or judgment for investors in the class period? How might this litigation affect Tempus AI's share price volatility in the short‑term (next few days) and medium‑term (weeks to months)? Will the lawsuit trigger any credit rating downgrades or affect the company’s ability to raise capital? Are there any similar past lawsuits against Temp- AI or its peers, and how were they resolved? What specific allegations are being made (e.g., fraud, misrepresentation, securities law violations) and how strong are the legal claims? How many investors are expected to join the class, and what is the total amount of alleged losses? Could this lawsuit lead to changes in management, corporate governance, or strategic direction at Tempus AI? What impact might the lawsuit have on existing partnerships, customer contracts, or supplier relationships? Will this litigation affect any pending or upcoming financing transactions for Tempus AI? How does the market's perception of this lawsuit compare to other recent litigation in the biotech/AI sector? What are the potential regulatory or SEC implications for Tempus AI beyond the class action?